MicroPhage Names Don Mooney to Serve as New CEO
Complete the form below to unlock access to ALL audio articles.
MicroPhage, Inc. has announced that Don Mooney has been named as the new Chief Executive Officer of the company effective February 3, 2011.
"The board selected Don on the basis of his deep diagnostics experience and proven leadership abilities particularly in launching new products, handling regulatory issues and creating effective strategic partnerships," said Gary Mesch, Executive Chairman of the Board for MicroPhage. "Don seems to fit very well with the MicroPhage team and brings strong decision-making skills and vision to guide the company through these next critical months and years as we commercialize the business. We are very pleased that he has chosen to join the team."
Don is an experienced leader in clinical diagnostics most recently serving as President and Chief Executive Officer of ProteoGenix, an early stage diagnostics company developing products in the fetal-maternal market. Prior to ProteoGenix, Don served as Vice President and Chief Operating Officer for Focus Diagnostics, Inc., an infectious disease company with both laboratory services and global diagnostic products.
Don helped engineer the acquisition of Focus by Quest Diagnostics in July 2006. Prior to that, Don held positions as President of B&L Surgical Group, VP Commercial Operations at Ortho Clinical Diagnostics, a J&J Company, and VP Marketing Operations at Ciba Corning/Chiron Diagnostics.
"I am thrilled to join MicroPhage at this point in its development," said Mooney. "Microphage technology offers solutions that save lives and reduce hospital costs. With its first novel product on the market in Europe and commercialization efforts under way in the U.S., I believe the company is poised to realize its full potential."
Mooney succeeds Drew Smith, company Chief Science Officer, who was named interim CEO in July. "I am proud of the MicroPhage team for its achievements in the last seven months. The team remains motivated and I look forward to working under Don's leadership," said Smith. Smith will remain CSO and will continue to lead the company's scientific efforts.
